← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Sapience Therapeutics, Inc.
Harrison, NY
$4,682,038
Total funding
5
Grants
Funding over time
peak $2.2M · FY2020–24$2.5M$1.9M$1.3M$625K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,682,038 · 5
By mechanism
R44$3,429,465 · 2
R43$1,252,573 · 3
Investigators at Sapience Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer$1,362,268
R44 · FY2023 · CA
Efficacy and PK/PD of a C/EBP beta antagonist in orthotopic breast cancer$803,479
R44 · FY2023 · CA
Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer$632,111
R44 · FY2024 · CA
Efficacy and PK/PD of a C/EBP beta antagonist in orthotopic breast cancer$631,607
R44 · FY2022 · CA
Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer$409,295
R43 · FY2021 · CA
Inhibition of SARS-CoV-2 infection with a pan-coronavirus anti-viral peptide$299,860
R43 · FY2021 · AI
Inhibition of SARS-CoV-2 infection with a pan-coronavirus anti-viral peptide$288,178
R43 · FY2022 · AI
Efficacy and PK/PD of a C/EBP beta antagonist in orthotopic breast cancer$255,240
R43 · FY2020 · CA